PMOS One Year Later: What the PCOS Rename Actually Changed for Peptide Protocols

May 2026 changed the language women use for one of the most common endocrine conditions on the planet. A Lancet consensus paper formally renamed polycystic ovary syndrome (PCOS) to polymetabolic ovarian syndrome (PMOS) — a change that had been building for years as clinicians grew tired of a name that fixated on cysts while the underlying condition is fundamentally metabolic. Enough months have passed to ask the real question: what has changed, and what has stayed exactly the same, for peptide protocols aimed at this population?

What the Rename Actually Fixed

PCOS has always been a poor name for the condition. The ultrasound finding it references — multiple small follicles on the ovaries — is neither necessary nor sufficient for the diagnosis, and it distracted from the central metabolic story: insulin resistance, chronic low-grade inflammation, androgen excess, and a lipid/glucose picture that overlaps significantly with type 2 diabetes and metabolic syndrome. Renaming to PMOS put "metabolic" in the diagnostic label where it belongs.

Practical downstream effects, one year in:

• Insurance coding is updating. Slowly. ICD-10 has not fully caught up, but new patient-facing materials from major professional societies now use PMOS as the primary term with PCOS as a legacy synonym.
• Metabolic-first treatment framing is easier to justify. Metformin, GLP-1 agonists, and inositol supplementation were always defensible for PCOS; they are now the default in more guidelines.
• The "just lose weight" reflex is finally receding. A name that emphasizes metabolic dysregulation reframes obesity as a downstream feature, not a lifestyle failure. This is overdue and good.

What Did Not Change: The Peptide Question

The mechanisms that make peptides interesting for PMOS management are the same ones that made them interesting for PCOS management. Nothing was reclassified, no new peptides gained approval for the indication, and the honest evidence picture remains the same:

The GLP-1 Question, Post-Rename

The most consequential real-world change for PMOS patients in 2026 has nothing to do with the rename — it is the arrival of orforglipron (Foundayo), the first FDA-approved oral GLP-1 receptor agonist, at $149/month with 12.4% weight loss at 36mg. For PMOS patients who cannot tolerate injections or whose insurance blocks brand injectables, an oral option changes the treatment conversation entirely. Add TrumpRx's brand-injection pricing at $149–$349/month and the compounded-vs-brand economics that dominated 2024–2025 have quietly shifted.

None of this is technically PMOS-labeled. All of it is being used off-label by women with PMOS, prescribed by clinicians who understand the metabolic picture better now that the diagnostic label reinforces it.

The Fertility Angle

PMOS is the leading cause of anovulatory infertility. Peptide research relevant here — particularly kisspeptin-10's role in modulating the hypothalamic-pituitary-gonadal axis — remains firmly in research territory, but it is the compound worth watching for the medium-term future. Our kisspeptin fertility deep-dive covers the trials in progress.

The Practical Bottom Line

The rename validated what informed clinicians already knew: this is a metabolic condition. Peptide-adjacent treatment options for the metabolic dimension — approved GLP-1s primarily — are more accessible and affordable than at any time in the condition's history under either name. The peptide-research territory beyond approved GLP-1s remains what it was: interesting, undercharacterized, and not something to run without a physician's involvement.

For prescribed, licensed care, Veritide's provider comparisons include several women's-health-focused telehealth clinics handling PMOS management.